Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.

Cohen, A T; Hamilton, M; Bird, A; Mitchell, S A; Li, S; Horblyuk, R; Batson, S

Cohen, A T; Hamilton, M; Bird, A; Mitchell, S A; Li, S; Horblyuk, R; Batson, S.

Affiliation

Cohen AT; Guy's and St Thomas' Hospitals, King's College, London, United Kingdom.
Hamilton M; BMS, Princeton, United States of America.
Bird A; Pfizer, Walton Oaks, United Kingdom.
Mitchell SA; Abacus International, Bicester, United Kingdom.
Li S; BMS, Princeton, United States of America.
Horblyuk R; Pfizer, New York, United States of America.
Batson S; Abacus International, Bicester, United Kingdom.

PLoS One ; 11(8): e0160064, 2016.

Article in En | MEDLINE | ID: mdl-27487187

Subject(s)

Anticoagulants/administration & dosage; Venous Thromboembolism/drug therapy; Venous Thromboembolism/prevention & control; Administration, Oral; Anticoagulants/adverse effects; Clinical Trials, Phase III as Topic/statistics & numerical data; Dabigatran/administration & dosage; Dabigatran/adverse effects; Humans; Long-Term Care; Network Meta-Analysis; Pyrazoles/administration & dosage; Pyrazoles/adverse effects; Pyridones/administration & dosage; Pyridones/adverse effects; Randomized Controlled Trials as Topic/statistics & numerical data; Rivaroxaban/administration & dosage; Rivaroxaban/adverse effects; Treatment Outcome; Venous Thromboembolism/epidemiology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Venous Thromboembolism / Anticoagulants Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2016 Document type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google